GEN - Genetic Engineering and Biotechnology NewsFeb 2022
Intellia Therapeutics acquires Rewrite Therapeutics for up to **$200 million**, integrating its **DNA-writing platform** to broaden CRISPR-based genome editing capabilities. The move targets diseases outside Intellia’s current pipeline, leveraging Rewrite’s technology to explore new therapeutic applications. Intellia, a leader in CRISPR therapeutics, aims to expand its toolkit for precision genome modification.
Intellia Therapeutics acquires a UC Berkeley-based DNA writing startup for $200 million to bolster its gene editing pipeline. The move follows Moderna’s entry into gene editing, prompting Intellia to explore complementary technologies. CEO John Leonard confirms the company remains open to expanding its target areas through acquisitions or partnerships.
Intellia Therapeutics acquires Rewrite Therapeutics, a private biotech firm specializing in DNA writing technologies. The move expands Intellia’s CRISPR-based genome editing portfolio, combining its clinical-stage curative therapeutics with Rewrite’s novel approaches. Both companies focus on advancing precision genetic medicine.